Guidelines & Clinical Resources Guidelines and Position PapersExpandBSH Recommendations for lab testing in AML (Mehta et al. 2022) BSH Guidance for older adults with frailty (Dennis et al 2022) ELN MRD Guidelines (Cloos et al 2025) ELN Genetic risk classification for less-intensive therapies (Dohner et al 2024) ELN Guidelines for diagnosis and management of AML (Dohner et al 2022) Best practice consensus guidelines on germline predisposition to haematological malignancies (Speight et al 2023) BSH Guidelines on Pregnancy in AML (Ali et al 2015) Digital ResourcesExpandAML60+: Risk Classification for older patients treated with intensive chemotherapy AML Relapse Score: Outcome prediction for patients at 1st relapse PRISM-AML: Prognostic risk model for patients treated with Venetoclax-based lower intensity treatments AML Companion App Treatment consensus recommendations by UK experts for induction treatment and transplant decisions in 1st remission. ELN 2025 AML MRD App Featured Papers Latest international update for how to use MRD in clinical practice, developed by members of the ELN-DAVID MRD Working Party, including recommendations for ultra-high sensitivity FLT3 NGS MRD testing. The NCRI AML18 trial: CPX-351 vs DA_Mylotarg in non-adverse risk AML (Knapper et al 2026) Clinical Resources Guidelines & Clinical Resources AML Relapse (MDT) Approved UK AML Treatments
